证券代码：002317 公告编号：2026-011 广东众生药业股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开 了第八届董事会第二十八次会议和第八届监事会第二十八次会议，审议通过了 《关于使用闲置自有资金进行委托理财的议案》，同意公司及子公司（公司合并 报表范围内的子公司）在保障日常生产经营以及项目建设资金需求，有效控制风 险的前提下，使用不超过人民币 40,000.00 万元的闲置自有资金进行委托理财， 期限为本次董事会审议通过之日起十二个月内，期限内任一时点的交易金额不超 过人民币 40,000.00 万元。在上述期限及额度内，资金可滚动使用。本投资事项 将在上述额度内，授权董事长具体实施相关事宜。 上述具体内容详见公司于 2025 年 10 月 31 日刊载在《证券时报》《上海证券 报》和巨潮资讯网（www.cninfo.com.cn）的相关公告。 为提高闲置自有资金使用效率，在确保公司正常经营的前提下 ...

来源：市场资讯 有投资者在互动平台向众生药业提问："你好，董秘！上次您回答了RAY1225已经被FDA批准开展临床 二期研究。我想问的是公司准备如何开展，比如说准备自己单独开展还是和国外哪个药企合作？目前什 么进度，如果没开始，预计什么时候开始？麻烦不要用'公司历来重视海外市场'这样的空话来回答好 吗？" 针对上述提问，众生药业回应称："您好！公司的RAY1225注射液已获得FDA批准在美国开展超重或肥 胖患者的II期临床研究。公司积极寻求国际合作，组织开展国际多中心临床研究，争取早日完成相关研 究，申报药物上市，为广大患者提供更多治疗选择。谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

证券日报网讯2月10日，众生药业（002317）在互动平台回答投资者提问时表示，公司与齐鲁制药签署 RAY1225注射液项目许可协议。目前已收到对方支付的首付款，将有效补充公司的现金流，优化公司 现金流结构，对公司的未来经营发展将产生积极影响。 ...

格隆汇2月10日丨众生药业(002317.SZ)在投资者互动平台表示，公司正在积极推进ZSP1601片IIb期临床 试验。 ...

众生药业（002317.SZ）2月10日在投资者互动平台表示，公司与齐鲁制药签署RAY1225注射液项目许可 协议。目前已收到对方支付的首付款，将有效补充公司的现金流，优化公司现金流结构，对公司的未来 经营发展将产生积极影响。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司1月和齐鲁制药达成了RAY1225的授权协议，请问 该协议的2亿首付款是否已收到，本次授权是否会给公司本季度和本年的财务数据带来积极的影响？ ...

（记者 王晓波） 众生药业（002317.SZ）2月10日在投资者互动平台表示，公司正在积极推进ZSP1601片IIb期临床试验。 公司争取早日完成相关研究，申报药物上市，为广大患者提供更多治疗选择。 每经AI快讯，有投资者在投资者互动平台提问：1601的数据什么时候能出来？数据结果怎么样？ ...

Group 1: Market Overview - The market sentiment has improved, leading to a broad-based rebound in major indices, with the Shanghai Composite Index rising by 1.41% to close at 4123.09 points [5][7] - The Wind All A Index increased by 1.89%, while the ChiNext Index surged by 2.98%, indicating strong performance in the innovation and growth sectors [7][10] - Small-cap stocks outperformed larger stocks, with the CSI 1000 Index rising by 2.26%, while the CSI 50 Index only increased by 1.45% [8][10] Group 2: Industry Dynamics - A draft national standard for prepared dishes has been released, aiming to ensure food safety and promote high-quality development in the industry [24][25] - In January 2026, the sales of excavators in China saw a year-on-year growth of 49.5%, with domestic sales increasing by 61.4% and exports rising by 40.5% [26][27] Group 3: Company Updates - Nicheng Co., Ltd. (603775.SH) announced an investment to acquire a 10.89% stake in Dongfang Jinxin Co., Ltd. for 166 million yuan and plans to increase its investment by 100 million yuan [28][29] - Weizhi Xiang (605089.SH) is innovating its business model by testing a "downstream market first" approach and expanding its channel through a "city partner" plan targeting lower-tier markets [30][31] - Zhongsheng Pharmaceutical (002317.SZ) reported positive results from Phase III clinical trials for its innovative drug, Anladiwei, indicating effective treatment for influenza in children and adolescents [32][33]

Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has approved the use of idle self-owned funds for entrusted wealth management, with a limit of up to RMB 400 million for a period of twelve months [2] Investment Details - The company’s wholly-owned subsidiary, Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd., has signed an agreement with Dongguan Branch of Bank of Communications to invest RMB 50 million in a structured deposit product [2] - The product is a principal-protected floating return type, with a term of 22 days and an expected annualized return rate of 1.00% to 2.10% [4][2] Risk Control Measures - The company will adhere to prudent investment principles and strictly follow the board-approved investment limits [8] - Regular market analysis and adjustments to investment strategies will be conducted to mitigate risks [8] - A detailed management system for entrusted wealth management has been established to prevent investment risks [8] Impact on the Company - The company aims to enhance the efficiency of idle funds and improve cash asset returns without affecting normal business operations [9] - Engaging in wealth management is expected to contribute positively to the overall performance of the company and benefit all shareholders [9]

证券代码：002317 公告编号：2026-010 广东众生药业股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开 了第八届董事会第二十八次会议和第八届监事会第二十八次会议，审议通过了 《关于使用闲置自有资金进行委托理财的议案》，同意公司及子公司（公司合并 报表范围内的子公司）在保障日常生产经营以及项目建设资金需求，有效控制风 险的前提下，使用不超过人民币 40,000.00 万元的闲置自有资金进行委托理财， 期限为本次董事会审议通过之日起十二个月内，期限内任一时点的交易金额不超 过人民币 40,000.00 万元。在上述期限及额度内，资金可滚动使用。本投资事项 将在上述额度内，授权董事长具体实施相关事宜。 上述具体内容详见公司于 2025 年 10 月 31 日刊载在《证券时报》《上海证券 报》和巨潮资讯网（www.cninfo.com.cn）的相关公告。 3、币种：人民币 4、产品期限：22 天 为提高闲置自 ...

Group 1 - Company Saisir signed a cooperation agreement with the Shapingba District Government of Chongqing, establishing a new company funded by the separation of existing assets related to blue electric vehicles [1] - The new company will have a shareholding structure where the SPV holds approximately 33.5%, other investors hold about 18.5%, and the company and its designated entities hold around 32% [1] - The new company's board will consist of 5 members, with the company appointing 1 member [1] Group 2 - Yunlu Co., Ltd. announced that the detention measures against its Chairman and General Manager, Li Xiaoyu, have been lifted, allowing him to resume his duties [2] - Lin Yang Energy's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan within the next 12 months [3] - Zhongfu Shenying's controlling shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 27 million shares [4] Group 3 - Anlu Technology's shareholders, including several investment funds, plan to collectively reduce their stake by up to 4% [5] - Jinfeng Technology is in the planning stage of a share acquisition, with its controlling shareholder intending to transfer 6% of the company's shares [6] - Shenjian Co., Ltd. reported that its revenue from the commercial aerospace sector is less than 1% of its total revenue, indicating limited contribution from this segment [7] Group 4 - Guolian Minsheng plans to increase its investment in Minsheng Securities by 200 million yuan, with the funds sourced from a specific stock issuance [8] - Zhongsheng Pharmaceutical's subsidiary has reported positive results from two Phase III clinical trials for its innovative drug, indicating effective treatment for influenza in children and adolescents [9] - Mingguan New Materials has decided to terminate its investment in a solar backplane and functional film production project due to industry overcapacity and declining profitability [10] Group 5 - Huading Co., Ltd.'s controlling shareholder plans to publicly solicit buyers for a 6% stake in the company [11] - Tiancheng Auto Control's subsidiary has received a notification to supply passenger car seats for a major automotive client, with a project lifecycle value of 2.3 billion yuan [12] - Shanshan Co., Ltd. signed a restructuring investment agreement that may lead to a change in its controlling shareholder to Anhui State-owned Assets Supervision and Administration Commission [13] Group 6 - Sichuan Changhong intends to transfer 58.33% of its subsidiary's equity to its controlling shareholder for 33.1245 million yuan, as the subsidiary's business has ceased operations [14] - Ruili Kemi is planning to acquire a 16% stake in its subsidiary, with the stock being suspended from trading [15] - Yongtai Technology is also planning to purchase a 25% stake in Yongtai High-tech from Ningde Times, with its stock suspended from trading as well [16][17]